Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 16/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6362980 | 0.91 | LTA4H (0.74) | LTA4HKCNH2CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL4694644 | 0.88 | LTA4H (0.60) | LTA4HKCNH2CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL4692397 | 0.83 | LTA4H (0.75) | LTA4HKCNH2 | |
| SCHEMBL4693430 | 0.83 | LTA4H (0.74) | LTA4HKCNH2CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL4709368 | 0.82 | LTA4H (0.75) | LTA4HKCNH2 | |
| SCHEMBL3628094 | 0.82 | LTA4H (0.67) | LTA4HKCNH2CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL4692427 | 0.82 | LTA4H (0.71) | LTA4HKCNH2CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL4709093 | 0.82 | LTA4H (0.74) | LTA4HKCNH2CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL4690998 | 0.81 | LTA4H (0.67) | LTA4HKCNH2CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL1896239 | 0.81 | LTA4H (1.00) | LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793602-A1 | TREATMENT OF AGING-ASSOCIATED DISEASE WITH MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Alkahest, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043379-A1 | LTA4H Modulators | LTA4H, LTB4R, LTB4R2 | LTA4H 1/4885KCNH2 3429/4885CYP3A4 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.